JP2024038327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024038327A5 JP2024038327A5 JP2024002319A JP2024002319A JP2024038327A5 JP 2024038327 A5 JP2024038327 A5 JP 2024038327A5 JP 2024002319 A JP2024002319 A JP 2024002319A JP 2024002319 A JP2024002319 A JP 2024002319A JP 2024038327 A5 JP2024038327 A5 JP 2024038327A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- composition
- protein
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 79
- 239000002773 nucleotide Substances 0.000 claims 66
- 108090000623 proteins and genes Proteins 0.000 claims 47
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 32
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 28
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 26
- 102000004169 proteins and genes Human genes 0.000 claims 25
- 125000006850 spacer group Chemical group 0.000 claims 25
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 claims 22
- 101710085848 Angiopoietin-related protein 3 Proteins 0.000 claims 22
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 20
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 18
- 108020004999 messenger RNA Proteins 0.000 claims 18
- 230000004568 DNA-binding Effects 0.000 claims 17
- 229940113082 thymine Drugs 0.000 claims 16
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 14
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 14
- 229940029575 guanosine Drugs 0.000 claims 14
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 13
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims 13
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 13
- 229940035893 uracil Drugs 0.000 claims 13
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 10
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 10
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 10
- 229940045145 uridine Drugs 0.000 claims 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 9
- 229960005305 adenosine Drugs 0.000 claims 9
- 108020005067 RNA Splice Sites Proteins 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 229930024421 Adenine Natural products 0.000 claims 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 5
- 229960000643 adenine Drugs 0.000 claims 5
- 229940104302 cytosine Drugs 0.000 claims 5
- 238000010459 TALEN Methods 0.000 claims 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 4
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims 3
- 102000055025 Adenosine deaminases Human genes 0.000 claims 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 3
- 108091036066 Three prime untranslated region Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 102000008682 Argonaute Proteins Human genes 0.000 claims 2
- 108010088141 Argonaute Proteins Proteins 0.000 claims 2
- 108091033409 CRISPR Proteins 0.000 claims 2
- 108700004991 Cas12a Proteins 0.000 claims 2
- 102100026846 Cytidine deaminase Human genes 0.000 claims 2
- 108010031325 Cytidine deaminase Proteins 0.000 claims 2
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 claims 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 230000030648 nucleus localization Effects 0.000 claims 2
- 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 claims 1
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical group O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims 1
- 108020005004 Guide RNA Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063007803P | 2020-04-09 | 2020-04-09 | |
| US202063007797P | 2020-04-09 | 2020-04-09 | |
| US63/007,803 | 2020-04-09 | ||
| US63/007,797 | 2020-04-09 | ||
| US202063045033P | 2020-06-26 | 2020-06-26 | |
| US202063045032P | 2020-06-26 | 2020-06-26 | |
| US63/045,033 | 2020-06-26 | ||
| US63/045,032 | 2020-06-26 | ||
| US202163136087P | 2021-01-11 | 2021-01-11 | |
| US63/136,087 | 2021-01-11 | ||
| PCT/US2021/026729 WO2021207710A2 (en) | 2020-04-09 | 2021-04-09 | Base editing of angptl3 and methods of using same for treatment of disease |
| JP2022562030A JP7457833B2 (ja) | 2020-04-09 | 2021-04-09 | Ａｎｇｐｔｌ３の塩基編集および疾患の処置のためにこれを使用する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562030A Division JP7457833B2 (ja) | 2020-04-09 | 2021-04-09 | Ａｎｇｐｔｌ３の塩基編集および疾患の処置のためにこれを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024038327A JP2024038327A (ja) | 2024-03-19 |
| JP2024038327A5 true JP2024038327A5 (https=) | 2025-05-14 |
Family
ID=78022701
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562030A Active JP7457833B2 (ja) | 2020-04-09 | 2021-04-09 | Ａｎｇｐｔｌ３の塩基編集および疾患の処置のためにこれを使用する方法 |
| JP2022562027A Active JP7457832B2 (ja) | 2020-04-09 | 2021-04-09 | Ｐｃｓｋ９の塩基編集および疾患の処置のためにこれを使用する方法 |
| JP2024002319A Pending JP2024038327A (ja) | 2020-04-09 | 2024-01-11 | Ａｎｇｐｔｌ３の塩基編集および疾患の処置のためにこれを使用する方法 |
| JP2024002316A Pending JP2024038326A (ja) | 2020-04-09 | 2024-01-11 | Ｐｃｓｋ９の塩基編集および疾患の処置のためにこれを使用する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562030A Active JP7457833B2 (ja) | 2020-04-09 | 2021-04-09 | Ａｎｇｐｔｌ３の塩基編集および疾患の処置のためにこれを使用する方法 |
| JP2022562027A Active JP7457832B2 (ja) | 2020-04-09 | 2021-04-09 | Ｐｃｓｋ９の塩基編集および疾患の処置のためにこれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002316A Pending JP2024038326A (ja) | 2020-04-09 | 2024-01-11 | Ｐｃｓｋ９の塩基編集および疾患の処置のためにこれを使用する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US12029795B2 (https=) |
| EP (3) | EP4133072A4 (https=) |
| JP (4) | JP7457833B2 (https=) |
| KR (2) | KR20230016175A (https=) |
| CN (2) | CN116096429A (https=) |
| AU (4) | AU2021252991B2 (https=) |
| BR (2) | BR112022020407A2 (https=) |
| CA (2) | CA3179863A1 (https=) |
| GB (8) | GB2613457B (https=) |
| IL (2) | IL297193A (https=) |
| MX (1) | MX2022012683A (https=) |
| PH (2) | PH12022553015A1 (https=) |
| WO (3) | WO2021207710A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3585895A1 (en) | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Compositions and methods for gene editing |
| MX2022012683A (es) * | 2020-04-09 | 2023-01-11 | Verve Therapeutics Inc | Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades. |
| WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| CA3235827A1 (en) * | 2021-10-21 | 2023-04-27 | Wei Hsi Yeh | Genome editing compositions and methods for treatment of retinitis pigmentosa |
| WO2023166425A1 (en) * | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions |
| US20230293646A1 (en) * | 2022-03-21 | 2023-09-21 | Crispr Therapeutics Ag | Methods and compositions for treating lipoprotein-related diseases |
| CA3256897A1 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for the administration of nucleic acids and their methods of use |
| GB2634837A (en) | 2022-06-07 | 2025-04-23 | Scribe Therapeutics Inc | Compositions and methods for the targeting of PCSK9 |
| WO2024061296A2 (en) * | 2022-09-22 | 2024-03-28 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease |
| KR20250124819A (ko) * | 2022-12-21 | 2025-08-20 | 인텔리아 테라퓨틱스, 인크. | 프로단백질 전환효소 서브틸리신 켁신 9(pcsk9) 편집을 위한 조성물 및 방법 |
| WO2024152058A1 (en) * | 2023-01-13 | 2024-07-18 | The Trustees Of The University Of Pennsylvania | Compositions and methods for the treatment of hereditary tyrosinemia type 1 |
| WO2024175550A1 (en) * | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| CN121358859A (zh) * | 2023-03-20 | 2026-01-16 | 维乎医疗有限公司 | 用于治疗心血管疾病的lpa基因的基于切口酶的体内编辑 |
| CN118813611B (zh) * | 2023-04-19 | 2025-09-16 | 清华大学 | 一种基于rna核酶的dear核酸操纵系统及其应用 |
| WO2025006782A2 (en) * | 2023-06-30 | 2025-01-02 | Chroma Medicine, Inc. | Guide rna compositions |
| CN121752723A (zh) * | 2023-08-31 | 2026-03-27 | 正基基因科技有限公司 | 编码crispr相关蛋白的核酸及其应用 |
| WO2025054363A1 (en) * | 2023-09-05 | 2025-03-13 | Cornell University | Minigene cassettes, recombinant polynucleotides, and methods of their use |
| WO2025064656A1 (en) * | 2023-09-19 | 2025-03-27 | Beam Therapeutics Inc. | Compositions and methods for altering a nucleobase in a lipoprotein(a) polynucleotide |
| CN117587013B (zh) * | 2023-11-27 | 2024-06-14 | 湖南师范大学 | 一种血管发育异常的斑马鱼模型的构建方法 |
| CN117568313B (zh) * | 2024-01-15 | 2024-04-26 | 上海贝斯昂科生物科技有限公司 | 基因编辑组合物及其用途 |
| CN121022805A (zh) * | 2024-02-26 | 2025-11-28 | 深圳信立泰药业股份有限公司 | 用于pcsk9基因修饰或编辑的组合物及其使用方法 |
| WO2025184520A1 (en) * | 2024-02-29 | 2025-09-04 | Intellia Therapeutics, Inc. | Compositions and methods for angiopoietin like 3 (angptl3) editing |
| JP2025139413A (ja) * | 2024-03-12 | 2025-09-26 | サミー株式会社 | 遊技機 |
| WO2026020120A1 (en) * | 2024-07-19 | 2026-01-22 | University Of Massachusetts | Increasing cas9 genome editing fidelity through attenuation of guide rna watson-crick base pairing potential |
| CN120130446B (zh) * | 2025-03-10 | 2026-01-20 | 苏州系统医学研究所 | 一种制备疾病动物模型的方法及其应用 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU733310C (en) | 1997-05-14 | 2001-11-29 | University Of British Columbia, The | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| EP1514933A1 (en) | 1999-07-08 | 2005-03-16 | Research Association for Biotechnology | Secretory protein or membrane protein |
| US20030119038A1 (en) | 1999-09-09 | 2003-06-26 | Bingham Brendan William | NARC1, novel subtilase-like homologs |
| US7029895B2 (en) | 1999-09-27 | 2006-04-18 | Millennium Pharmaceuticals, Inc. | 27411, a novel human PGP synthase |
| EP1226243A2 (en) | 1999-10-22 | 2002-07-31 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules derived from rat brain and programmed cell death models |
| JP2003513662A (ja) | 1999-11-09 | 2003-04-15 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | １５個のヒト分泌タンパク質 |
| EP1235914A2 (en) | 1999-11-24 | 2002-09-04 | Joseph Rosenecker | Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells |
| EP1257572A2 (en) | 2000-02-07 | 2002-11-20 | Millennium Pharmaceuticals, Inc. | Narc-1, subtilase-like homologs |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2001098468A2 (en) | 2000-06-16 | 2001-12-27 | Incyte Genomics, Inc. | Proteases |
| WO2002014358A2 (en) | 2000-08-11 | 2002-02-21 | Eli Lilly And Company | Novel secreted proteins and their uses |
| JP2005500005A (ja) | 2000-12-08 | 2005-01-06 | インサイト・ゲノミックス・インコーポレイテッド | タンパク質修飾分子とメンテナンス分子 |
| DE10109897A1 (de) | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| EP1379264A4 (en) | 2001-03-21 | 2009-07-08 | Human Genome Sciences Inc | HUMAN SECRETED PROTEINS |
| US7858117B2 (en) | 2002-02-21 | 2010-12-28 | Novosom Ag | Amphoteric liposomes and their use |
| EP1440981A3 (en) | 2003-01-21 | 2005-11-23 | Research Association for Biotechnology | Full-length human cdna |
| EP1471152A1 (en) | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
| DE102004054730A1 (de) | 2004-03-28 | 2006-05-11 | Novosom Ag | Serumstabile amphotere Liposomen |
| US20060051405A1 (en) | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
| US20070087045A1 (en) | 2005-10-14 | 2007-04-19 | Industrial Technology Research Institute | Lipid carrier and method of preparing the same |
| US20100040610A1 (en) | 2006-11-07 | 2010-02-18 | Ayesha Sitlani | Antagonists of pcsk9 |
| TWI516501B (zh) * | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| CN112301024A (zh) * | 2013-03-15 | 2021-02-02 | 通用医疗公司 | 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性 |
| EP3041934A1 (en) * | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| FR3012370B1 (fr) | 2013-10-30 | 2017-04-14 | Michelin & Cie | Armature de sommet pour pneumatique d'avion |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| PT3087183T (pt) * | 2013-12-24 | 2020-10-08 | Ionis Pharmaceuticals Inc | Modulação da expressão da proteína relacionada com angiopoietina 3 |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| CA2964796C (en) | 2014-10-17 | 2022-01-11 | The Penn State Research Foundation | Methods and compositions for multiplex rna guided genome editing and other rna technologies |
| MA41123A (fr) * | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
| US11279928B2 (en) * | 2015-06-29 | 2022-03-22 | Massachusetts Institute Of Technology | Compositions comprising nucleic acids and methods of using the same |
| PT3313829T (pt) | 2015-06-29 | 2024-07-08 | Acuitas Therapeutics Inc | Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos |
| US20180200186A1 (en) | 2015-07-09 | 2018-07-19 | Insmed Incorporated | Compositions and methods for treating lung diseases and lung injury |
| KR102405695B1 (ko) * | 2015-08-31 | 2022-06-03 | 엘지디스플레이 주식회사 | 유기 발광 표시 장치 및 그 제조 방법 |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| CA2947904A1 (en) * | 2015-11-12 | 2017-05-12 | Pfizer Inc. | Tissue-specific genome engineering using crispr-cas9 |
| CN109715801B (zh) * | 2015-12-01 | 2022-11-01 | 克里斯普治疗股份公司 | 用于治疗α1抗胰蛋白酶缺乏的材料和方法 |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| WO2017136794A1 (en) * | 2016-02-03 | 2017-08-10 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| LT3436077T (lt) | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| US10767175B2 (en) * | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| US10927383B2 (en) | 2016-06-30 | 2021-02-23 | Ethris Gmbh | Cas9 mRNAs |
| WO2018119514A1 (en) | 2016-12-28 | 2018-07-05 | Precision Nanosystems Inc. | Compositions for transfecting resistant cell types |
| KR102622411B1 (ko) * | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| SG10202106058WA (en) * | 2016-12-08 | 2021-07-29 | Intellia Therapeutics Inc | Modified guide rnas |
| KR20230125856A (ko) * | 2016-12-23 | 2023-08-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Pcsk9의 유전자 편집 |
| BR112019015797A2 (pt) | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação |
| TW201839136A (zh) * | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
| AU2018224380A1 (en) | 2017-02-22 | 2019-08-29 | Crispr Therapeutics Ag | Compositions and methods for treatment of proprotein convertase subtilisin/kexin type 9 (PCSK9)-related disorders |
| EP3585895A1 (en) | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Compositions and methods for gene editing |
| CN110678548A (zh) * | 2017-03-31 | 2020-01-10 | 埃吉诺维亚公司 | 抗病毒治疗剂 |
| WO2018191719A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipid delivery of therapeutic agents to adipose tissue |
| KR102761791B1 (ko) * | 2017-06-26 | 2025-02-05 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 crispr/cas-아데닌 데아미나아제 기반 조성물, 시스템 및 방법 |
| CN111801345A (zh) * | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| EP3437650A1 (en) * | 2017-07-31 | 2019-02-06 | Accanis Biotech F&E GmbH & Co KG | Treatment of local skin hypotrophy conditions |
| WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| KR102832035B1 (ko) | 2017-09-29 | 2025-07-09 | 인텔리아 테라퓨틱스, 인크. | 지질 나노파티클을 이용한 mRNA 전달의 체외 방법 |
| US20230140670A1 (en) | 2017-09-29 | 2023-05-04 | Intellia Therapeutics, Inc. | Formulations |
| WO2019067910A1 (en) | 2017-09-29 | 2019-04-04 | Intellia Therapeutics, Inc. | POLYNUCLEOTIDES, COMPOSITIONS AND METHODS FOR GENOMIC EDITION |
| WO2019213183A1 (en) | 2018-04-30 | 2019-11-07 | The Trustees Of The University Of Pennsylvania | In utero crispr-mediated therapeutic editing of genes |
| CN119570787A (zh) * | 2018-05-11 | 2025-03-07 | 比姆医疗股份有限公司 | 使用可编程碱基编辑器系统遏止病原性突变的方法 |
| US12157760B2 (en) * | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| AU2019282824C1 (en) * | 2018-06-08 | 2026-04-23 | Intellia Therapeutics, Inc. | Modified guide RNAS for gene editing |
| EP3847254A4 (en) | 2018-09-07 | 2022-08-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| WO2021056302A1 (en) | 2019-09-26 | 2021-04-01 | Syngenta Crop Protection Ag | Methods and compositions for dna base editing |
| GB2613225B (en) * | 2020-03-04 | 2024-01-03 | Verve Therapeutics Inc | Compositions and methods for targeted RNA delivery |
| MX2022012683A (es) | 2020-04-09 | 2023-01-11 | Verve Therapeutics Inc | Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades. |
| JP2023549011A (ja) * | 2020-09-15 | 2023-11-22 | ヴァーヴ・セラピューティクス，インコーポレーテッド | 遺伝子編集のための脂質製剤 |
-
2021
- 2021-04-09 MX MX2022012683A patent/MX2022012683A/es unknown
- 2021-04-09 CN CN202180043135.4A patent/CN116096429A/zh active Pending
- 2021-04-09 PH PH1/2022/553015A patent/PH12022553015A1/en unknown
- 2021-04-09 IL IL297193A patent/IL297193A/en unknown
- 2021-04-09 WO PCT/US2021/026729 patent/WO2021207710A2/en not_active Ceased
- 2021-04-09 WO PCT/US2021/026731 patent/WO2021207711A2/en not_active Ceased
- 2021-04-09 KR KR1020227038926A patent/KR20230016175A/ko active Pending
- 2021-04-09 BR BR112022020407A patent/BR112022020407A2/pt unknown
- 2021-04-09 GB GB2216693.8A patent/GB2613457B/en active Active
- 2021-04-09 IL IL297194A patent/IL297194A/en unknown
- 2021-04-09 JP JP2022562030A patent/JP7457833B2/ja active Active
- 2021-04-09 CN CN202180041917.4A patent/CN116096883A/zh active Pending
- 2021-04-09 US US17/918,057 patent/US12029795B2/en active Active
- 2021-04-09 EP EP21785068.4A patent/EP4133072A4/en active Pending
- 2021-04-09 GB GB2317179.6A patent/GB2625902B/en active Active
- 2021-04-09 GB GB2413232.6A patent/GB2632565B/en active Active
- 2021-04-09 BR BR112022020428A patent/BR112022020428A2/pt unknown
- 2021-04-09 AU AU2021252991A patent/AU2021252991B2/en active Active
- 2021-04-09 WO PCT/US2021/026732 patent/WO2021207712A2/en not_active Ceased
- 2021-04-09 JP JP2022562027A patent/JP7457832B2/ja active Active
- 2021-04-09 GB GB2216687.0A patent/GB2612452C/en active Active
- 2021-04-09 GB GB2316054.2A patent/GB2623891B/en active Active
- 2021-04-09 EP EP21784686.4A patent/EP4133071A4/en active Pending
- 2021-04-09 PH PH1/2022/553033A patent/PH12022553033A1/en unknown
- 2021-04-09 GB GB2413235.9A patent/GB2632566B/en active Active
- 2021-04-09 CA CA3179863A patent/CA3179863A1/en active Pending
- 2021-04-09 US US17/918,069 patent/US20230158174A1/en active Pending
- 2021-04-09 CA CA3179862A patent/CA3179862A1/en active Pending
- 2021-04-09 AU AU2021253959A patent/AU2021253959B2/en active Active
- 2021-04-09 GB GB2413218.5A patent/GB2632563B/en active Active
- 2021-04-09 KR KR1020227038947A patent/KR20230016176A/ko active Pending
- 2021-04-09 US US17/918,092 patent/US12115230B2/en active Active
- 2021-04-09 EP EP21783997.6A patent/EP4132591A4/en active Pending
- 2021-04-09 GB GB2413231.8A patent/GB2632564B/en active Active
-
2024
- 2024-01-11 JP JP2024002319A patent/JP2024038327A/ja active Pending
- 2024-01-11 JP JP2024002316A patent/JP2024038326A/ja active Pending
- 2024-02-20 US US18/582,406 patent/US20240390523A1/en active Pending
- 2024-10-02 US US18/904,423 patent/US20250152746A1/en active Pending
-
2025
- 2025-06-03 AU AU2025204143A patent/AU2025204143A1/en active Pending
- 2025-06-04 AU AU2025204175A patent/AU2025204175A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024038327A5 (https=) | ||
| JP2024038326A5 (https=) | ||
| JP6799058B2 (ja) | アレル選択的な遺伝子編集およびその使用 | |
| JP7698881B2 (ja) | Ｒｎａ編集のための化学修飾したオリゴヌクレオチド | |
| CN113994000A (zh) | 包括胞苷类似物的反义rna编辑寡核苷酸 | |
| CA2968336C (en) | Construct for site directed editing of an adenosine nucleotide in target rna | |
| Patanjali et al. | Construction of a uniform-abundance (normalized) cDNA library. | |
| TuRCHI et al. | Enzymatic completion of mammalian lagging-strand DNA replication. | |
| DE69331524T2 (de) | Verfahren zum spezifischen schneiden von rna-strängen | |
| US20180016601A1 (en) | Methods for Modulating Genome Editing | |
| CN114174510A (zh) | 添加了功能性碱基序列的靶标编辑指导rna | |
| AU2021312054A1 (en) | Antisense oligonucleotides for RNA editing | |
| JP2020512845A5 (https=) | ||
| JP2022519882A5 (https=) | ||
| CN105916983A (zh) | 用于高效且特异性靶向包含高度重复基序的dna序列的稀有切割核酸内切酶的设计 | |
| KR20260007576A (ko) | 변형된 가이드 rna | |
| AU2020263804A1 (en) | RNA editing inhibitors and methods of use | |
| WO2024196779A2 (en) | Optimized antisense sequences that enhance targeted rna editing by adar proteins | |
| Herman et al. | Vesicular stomatitis virus RNA polymerase can read through the boundary between the leader and N genes in vitro | |
| JP2024529400A5 (https=) | ||
| JP2024534639A5 (https=) | ||
| Chaix et al. | 3′-3′-linked oligonucleotides: Synthesis and stability studies | |
| EP0980379B1 (de) | Chimäre oligonucleotide und ihre verwendung | |
| WO2026019837A1 (en) | Compositions and methods for overcoming t-cell exhaustion | |
| Lewin | First success with reverse genetics |